top of page
JAZMINE
ZANIDATAMAB IN COMBINATION WITH TUCATINIB PLUS CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER
CLINICAL TRIAL DETAILS
TO DETERMINE THE RECOMMENDED PHASE II DOSE AND EVALUATE THE PRELIMINARY ANTITUMOR ACTIVITY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB PLUS CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
BREAST
12
120
Phase Ib/II
Spain
SET UP
TRIAL OVERVIEW
PRESS RELEASE
----
SCIENTIFIC IMPACT
-----
BLOG ARTICLES RELATED
----
TRIAL SITES
-----
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page